Syneos Health Inc

Syneos Health — INC Research Holdings — Merger or Acquisition (May 2017)

43 slides from Syneos Health's merger presentation, May 10, 2017

  1. Slide 1: INC Research + inVentiv Health Merger

    INC Research + inVentiv Health Merger Creating a Leading Global Biopharmaceutical Solutions Organization May 10, 2017

  2. Slide 2: Important Information

    Important Information 1 Forward-Looking Statements This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such

  3. Slide 3: Important Information (Cont'd) Non-GAAP Financial Measures

    Important Information (Cont’d) Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with GAAP, this presentation contains certain non-GAAP financial measures, including Adjusted Income from Operations, Adjusted Operating Margin, Adjusted Net Income (including Adju

  4. Slide 4: Purpose built to address market realities where clinical and commercial must work together

    INC Research + inVentiv Health Purpose built to address market realities where clinical and commercial must work together – sharing expertise, data and insights – to improve customer performance Infusing clinical insights into commercialization, and commercial expertise into clinical trials, to spee

  5. Slide 5: Transformational Strategic Combination

    Transformational Strategic Combination Industry Leader # 7 CRO # 6 CRO / #1 CCO Top 3 CRO / #1 CCO Critical mass in North America / Critical mass in North America, Global leader including APAC; EMEA; Sub-scale in APAC EMEA and APAC Top 3 global CRO in Japan Strong infrastructure; Additional scale an

  6. Slide 6: Creates the #2 Global Biopharmaceutical Solutions Company

    Creates the #2 Global Biopharmaceutical Solutions Company Clinical Commercial~$3.2 billion Top 3 CRO based #1 CCO based on net revenue on net revenue2016 Combined Net Revenue ~$60bn Total ~$150bn Total Addressable Market Addressable Market (~50% outsourcing penetration) (~16% outsourcing penetration

  7. Slide 7: Significant Value Creation Opportunities

    Significant Value Creation Opportunities Accelerating inVentiv Health margin Mid-to-high single digit accretion in 2018 expansion story 20% plus accretion in 2019 and beyond Identified and achievable annual cost 2017-2020 Combined Outlook synergies of ~$100 million High-single digits Net Revenue gro

  8. Slide 8: Key Transaction Highlights

    Key Transaction Highlights INC Research to issue common stock to inVentiv Health in an all-stock transaction Values inVentiv Health at an enterprise value of ~$4.6bn and combined company at an enterprise value Consideration of ~$7.4bn based on closing price of INC Research common stock on May 9, 201

  9. Slide 9: Global Biopharmaceutical Solutions Leader in Size and Scale

    Global Biopharmaceutical Solutions Leader in Size and Scale ($ in billions) 2016 Biopharmaceutical Solutions Net Revenue ~$7.7 ~$3.2 ~$2.9(1)~$2.8 ~~$2.5 ~$2.2~$2.1 ~$1.9~$1.9 ~$1.7~$1.6 ~$1.5 ~$1.0~$0.9(4) ~$0.4 (Covance) Employees(2) 50,000 22,000+ 10,000 15,000(3) 18,500 15,20018,6009,1009,20012,

  10. Slide 10: A Leader in End-to-End Drug Development Solutions

    A Leader in End-to-End Drug Development Solutions CRO CCO Full Service Real World Data Comm- Selling Medication Central Lab Phase I Phases II-IV FSP Evidence Analytics Consulting unications Solutions Adherence (Covance) (Ashfield) Note: Trademarks, service marks or trade names are the property of th

  11. Slide 11: A Strong, Well Diversified Business

    A Strong, Well Diversified Business Comprehensive Ability to Serve Customers of Diversified Customer Base End-to-End Solutions All Sizes Solutions Mix Biopharma Customer ConcentrationBiopharma Customer Type (Total Company)(Total Company) 30%30% 36% 55%53% 64% 15%17% CRO CCOTop 5Top 6-10OtherTop 20To

  12. Slide 12: Platform to Leverage Insights Across Continuum

    Platform to Leverage Insights Across Continuum Improves Performance Clinical Visibility and Therapeutic Experience Inform Commercialization Efforts CRO CCO Full Service Selling Solutions Communications Early Stage Strategic Resourcing Consulting Medication Adherence Commercial Pricing & Marketing In

  13. Slide 13: Clinical Research Organization Segment

    Clinical Research Organization Segment

  14. Slide 14: Critical Success Factors in Today's Global Clinical Development Market

    Critical Success Factors in Today’s Global Clinical Development Market Critical Scale Strong Geographic Presence Therapeutic Depth and Expertise Delivery Model Flexibility Ability to Deliver Solutions for Customers of All Sizes Understanding Market Challenges Building a better CRO to service custome

  15. Slide 15: Creates a Global Leader in Clinical Outsourcing

    Creates a Global Leader in Clinical Outsourcing Critical Scale ($ in billions) Clinical Development Net Revenue(1) ~$2.8 ~$2.1 ~$2.1 ~$1.6~$1.6~$1.5 ~$1.0~$1.0~$0.9 ~$0.4 (Covance) Strong Geographic Presence CRO Employees (~15,400) Support customers in 110+ countries Employees in 60+ countries 17% U

  16. Slide 16: Therapeutic Area Depth and Breadth of Delivery Models

    Therapeutic Area Depth and Breadth of Delivery Models Therapeutic Depth and Expertise Net Revenue by Therapeutic Area Deep expertise across all therapeutic areas, particularly in complex diseases to meet needs of the largest biopharma customers 3% 6% Oncology 8% 26% CNS Expanded expertise in oncolog

  17. Slide 17: Flexibility to Serve Customers of All Sizes

    Flexibility to Serve Customers of All Sizes Ability to Deliver Solutions for Customers of All Sizes Net Revenue by Biopharmaceutical Customer Type Combination of inVentiv Health’s strength with top 20 complements INC Research strength with SMID Strong stable revenue base from top 50 – ~$1.4bn 33%com

  18. Slide 18: Contract Commercial Organization Segment

    Contract Commercial Organization Segment

  19. Slide 19: Commercial Market Offers Attractive Growth Profile

    Commercial Market Offers Attractive Growth Profile Commercial Spending Landscape Projected CCO Market Development ($ in billions) ($ in billions) ~$250 $39 $36 $34 $31 $29 $27 $25 ~$150 ~16%22% outsourcing20%21% penetration18%19% 16%17% ~$25 SG&A OutsourcingCurrent2016201720182019202020212022 Spendi

  20. Slide 20: Biopharmaceutical Operating Challenges Demand New Commercial Solutions

    Biopharmaceutical Operating Challenges Demand New Commercial Solutions Challenges Existing Approaches Reduce SG&A Margin deterioration Optimize deployment of marketing and field assets Reimbursement and Refocus product portfolios around therapeutic access hurdles areas with depth of presence Expand

  21. Slide 21: Broadest Provider of Commercialization Solutions

    Broadest Provider of Commercialization Solutions Employees: ~6,400 Net Revenue:Adjusted EBITDA $1,186mmmargin of ~18% Selling Solutions CommunicationsConsultingMedication Adherence Field-based promotional Healthcare advertising Commercial strategy Highly flexible direct-to- solutions and planningpat

  22. Slide 22: Leading Global Provider Focused on High Value Commercial Solutions

    Leading Global Provider Focused on High Value Commercial Solutions / (Commercial only)(Integrated Engagement Services)(Ashfield) Selling Solutions (Tactical) Communications – Consulting Medication Adherence –Limited Data + Insight Key financial metrics ($ in millions) 2016 net revenue(1) $1,186 $796

  23. Slide 23: Expansive Data Assets Can Drive Insights and Improve Execution

    Expansive Data Assets Can Drive Insights and Improve Execution Pharmacy claims Trial protocol burden Longitudinal Rx Electronic medical records Prescriber interaction / Clinical performance preference Trial saturation Market access / competitive landscape Patient journey Patient and healthcare provi

  24. Slide 24: Financial Highlights

    Financial Highlights

  25. Slide 25: Significantly Accelerates Growth

    Significantly Accelerates Growth INC Research Standalone INC Research + inVentiv Health 2017 – 2020 CAGR Significantly increases addressable market 10% $1,030$1,0559% $810 $915 Highly diversified revenue sources Revenue Does not include revenue synergies from cross-selling No expected revenue disyne

  26. Slide 26: Identifiable and Achievable Cost Synergies and Meaningful Additional Upsides

    Identifiable and Achievable Cost Synergies and Meaningful Additional Upsides Corporate and administrative spending~$100 million run-rate Cost Rationalize clinical cost structurecost synergies fully Synergies Facility consolidationrealized within three IT systems consolidationyears post-close Up to a

  27. Slide 27: Meaningful Revenue Synergies From Cross-Selling

    Meaningful Revenue Synergies From Cross-Selling inVentiv Health’s hybrid and FSP offering into INC Research’s installed customer base Market Combined Clinical Scale and - Combined FSP offering spans monitoring, data, analytics, PVG, safety and investigator payments Service Offering Stronger therapeu

  28. Slide 28: Value Creation Through Successful Integrations

    Value Creation Through Successful Integrations 7 acquisitions since 200725 acquisitions since 2007 2 of which were transformational2 of which were transformational MDS Global ClinicalKendle InternationalPharmaNet / i3 Development Year 200920112011 Forecast Cost $9mm$41mm$28mm Synergies Cost Synergie

  29. Slide 29: Strong Pro Forma Credit Profile

    Strong Pro Forma Credit Profile HighlightsAnticipated Sources & Uses ($ in billions) Plan to opportunistically refinance capital structure, affording favorable terms, liquidity and flexibility New Term Loan B(2)$2.6 Equity Issued to inVentiv Health2.2 Long-term focus on deleveraging and optimizing w

  30. Slide 30: INC Research Q1 2017 Highlights

    INC Research Q1 2017 Highlights Key Operating Metrics – Adjusted Basis Three Months Ended March 31, $mm (except ratios and per share data) 2016 2017% Change Total Company: Net Service Revenue 249.0 252.11.2% Adjusted EBITDA 57.1 58.11.8% Adjusted EBITDA margin 22.9% 23.1%~20bps Adjusted EPS $0.58 $0

  31. Slide 31: Creating a Leading Global Biopharmaceutical Solutions Organization

    Creating a Leading Global Biopharmaceutical Solutions Organization Top 3 CRO / #1 CCO Global leader including APAC; Top 3 global CRO in Japan Substantial scale with 22,000+ FTEs Diversified and highly complementary customer base Deep therapeutic expertise, particularly complex diseases Flexibility a

  32. Slide 32: Appendix

    Appendix

  33. Slide 33: Commercial Business is Well-Positioned for Growth

    18 24 26 21 30 39 27 41 45 22 20 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Commercial Business is Well-Positioned for Growth 32 New drug approvals have been on a steady increase over the past decade however timing of approvals can be lumpy — 2016 decline (~50%) only 3rd down year since

  34. Slide 34: INC Research Q1 2017 Income Statement

    INC Research Q1 2017 Income Statement 33 Income Statement – Adjusted Basis Note: Due to rounding of specific line items, line item figures might not sum to subtotals. For a complete reconciliation of GAAP to Non-GAAP measures for the current and historical periods presented, please refer to slides 3

  35. Slide 35: INC Research Backlog Should Support Long-Term Growth

    $1,030 $957 $1,055(1) INC Research Backlog Should Support Long-Term Growth 34 Note: Due to rounding of specific line items, line item figures might not sum to subtotals. (1) 2017 revenue estimate represents the mid-point of the updated guidance range on slide 35 of this presentation. (2) CNS was upd

  36. Slide 36: INC Research Full Year 2017 Guidance

    INC Research Full Year 2017 Guidance 35 Note: Financial guidance takes into account a number of factors, including INC Research sales pipeline, existing backlog and expectations for net awards, current foreign currency exchange rates, current interest rates, and expected tax rate, and does not take

  37. Slide 37: INC Research Non-GAAP Financials

    INC Research Non-GAAP Financials 36 $mm Fiscal Year Ending December 31, 2014 2015 2016 Q1 ‘16 Q1 ‘17 LTM Net Income (loss) ($23.5) $117.0 $112.6 $17.4 $21.2 $116.4 Interest expense, net 52.8 15.4 11.8 3.0 3.0 11.8 Income tax provision (benefit) (4.7) 13.9 21.5 7.0 7.1 21.6 Depreciation and Amortizat

  38. Slide 38: INC Research Non-GAAP Financials (Cont'd)

    INC Research Non-GAAP Financials (Cont’d) 37 $mm Fiscal Year Ending December 31, 2014 2015 2016 Q1 ‘16 Q1 ‘17 Net Income (loss) ($23.5) $117.0 112.6 $17.4 $21.2 Amortization 32.9 37.9 37.9 9.5 9.5 Restructuring and other costs (a) 6.2 1.8 13.6 6.0 1.9 Stock based compensation (b) 3.4 5.1 14.0 2.8 5.

  39. Slide 39: INC Research Non-GAAP Financials (Cont'd)

    INC Research Non-GAAP Financials (Cont’d) 38 (a) Restructuring, CEO transition, and other costs consist primarily of: (i) severance costs associated with a reduction of workforce in line with the Company’s expectations of future business operations, (ii) transition costs associated with the change i

  40. Slide 40: inVentiv Health Financial Overview

    inVentiv Health Financial Overview 39 15.1% 14.4% 16.6% 18.0% 10.2% 11.4% 14.1% 16.5% 10.8% 11.4% 14.7% 17.9% $168 $207 $281 $364 2013 2014 2015 2016 $1,645 $1,806 $1,994 $2,211 2013 2014 2015 2016 ($ in millions) ($ in millions) % margin $865 $870 $948 $1,043 2013 2014 2015 2016 $93 $100 $139 $187

  41. Slide 41: inVentiv Health Estimated and Preliminary Q1 2017 Highlights

    inVentiv Health Estimated and Preliminary Q1 2017 Highlights 40 $mm (except ratios) Three Months Ended March 31, 2016 2017 % Change Total Company: Net Service Revenue 541.3 533.8(1) (1.4%) Adjusted EBITDA 85.0 96.7 13.7% Adjusted EBITDA margin 15.7% 18.1% ~240bps Selected Clinical Metrics: Net New B

  42. Slide 42: inVentiv Health Non-GAAP Financials

    inVentiv Health Non-GAAP Financials 41 $mm Fiscal Year Ending December 31, 2013 2014 2015 2016 Q1 ‘16 Q1 ‘17 LTM Net Income (loss) ($236.4) ($188.8) ($150.6) ($183.6) ($18.6) ($40.7) ($205.7) Interest expense, net 209.2 217.0 228.2 231.7 55.9 37.7 213.6 Income tax provision (benefit) 3.0 2.5 5.6 (8.

  43. Slide 43: inVentiv Health Non-GAAP Financials (Cont'd)

    inVentiv Health Non-GAAP Financials (Cont’d) 42 (a) Represents non-cash losses associated with the impairment of goodwill, intangible assets and other long-lived assets. (b) Represents stock-based compensation charges in the income statement. (c) Represents non-cash adjustments resulting from the re

INC Research Holdings — Merger or Acquisition (May 2017) on 6ix